GlassScriptPhysician profile
Anam Rizvi
NPI 1043746779
$32,593.80
in general payments reported to CMS, 2019-2025
10 companies · $26K in 2025
The $26K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,720 · 2024: $3,305 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $25K · Travel and Lodging: $3,810 · Food and Beverage: $3,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $25,000.00 |
| Travel and Lodging | $3,810.29 |
| Food and Beverage | $3,783.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30,130.65 | 2023-2025 | General - Therapies, Resolution 360 Clip, Apollo Esg System |
| Ovesco Endoscopy USA, INC. | $1,284.30 | 2024 | |
| Fujifilm Healthcare Americas Corporation | $528.56 | 2023-2024 | Fujifilm |
| Conmed Corporation | $250.82 | 2023-2024 | Conmed Biliary, Conmed Generators |
| Intra-Sana Laboratories | $149.68 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Endogastric Solutions, INC | $140.40 | 2023 | Esophyx |
| Novo Nordisk INC | $48.08 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.86 | 2023 | Gattex |
| Cook Medical LLC | $21.43 | 2025 | Fusion |
| Olympus America INC. | $16.02 | 2023 | Hanarostent Lowaxtm Duodenum/Pylorus(Nnn) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anam Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.